ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

CVAC Company Profile and Key Details

NASDAQ : CVAC

CureVac N.V.

$2.86

0.14+5.15%

At Close 4:00 PM

63.3

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

CVAC Stock Price Chart

Stock Price Today

CureVac N.V. (CVAC) stock surged +5.15%, trading at $2.86 on NASDAQ, up from the previous close of $2.72. The stock opened at $2.68, fluctuating between $2.68 and $2.87 in the recent session.

Stock Snapshot

2.72

Prev. Close

2.68

Open

641.52M

Market Cap

224.31M

Number of Shares

2.68

Day Low

2.87

Day High

5.61

P/E Ratio

41.74%

Free Float in %

0.51

EPS (TTM)

2.69

Book Value

-1.5

Cash Flow per Share

555.4K

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2025	2.68	2.88	2.68	2.86	554.98K
Apr 01, 2025	2.78	2.81	2.71	2.72	837.44K
Mar 31, 2025	2.93	2.93	2.72	2.77	1.18M
Mar 28, 2025	3.29	3.33	2.97	2.98	2.03M
Mar 27, 2025	2.85	2.90	2.78	2.80	539.55K
Mar 26, 2025	2.87	2.92	2.84	2.85	269.16K
Mar 25, 2025	3.08	3.10	2.91	2.91	356.37K
Mar 24, 2025	2.91	3.02	2.90	3.00	367.36K
Mar 21, 2025	2.98	2.98	2.83	2.89	973.22K
Mar 20, 2025	3.01	3.07	2.94	2.97	458.77K
Mar 19, 2025	3.01	3.11	3.01	3.04	360.8K
Mar 18, 2025	3.04	3.10	3.01	3.02	485.62K
Mar 17, 2025	3.01	3.11	3.01	3.07	346.6K
Mar 14, 2025	3.07	3.14	3.01	3.01	447.24K
Mar 13, 2025	3.16	3.18	3.03	3.03	335.36K
Mar 12, 2025	3.15	3.23	3.11	3.17	471.06K
Mar 11, 2025	2.92	3.20	2.87	3.16	943.94K
Mar 10, 2025	3.06	3.10	2.90	2.92	940.02K
Mar 07, 2025	3.13	3.19	3.04	3.04	509.94K
Mar 06, 2025	3.12	3.21	3.09	3.20	430.1K

Contact Details

TÃ¼bingen, 72076

Germany

Website: https://www.curevac.comContact: 497 071 98830

About Company

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Frequently Asked Questions

What is the current CureVac N.V. (CVAC) stock price?

CureVac N.V. (NASDAQ: CVAC) stock price is $2.86 in the last trading session. During the trading session, CVAC stock reached the peak price of $2.87 while $2.68 was the lowest point it dropped to. The percentage change in CVAC stock occurred in the recent session was 5.15% while the dollar amount for the price change in CVAC stock was $0.14.

CVAC's industry and sector of operation?

The NASDAQ listed CVAC is part of Biotechnology industry that operates in the broader Healthcare sector. CureVac N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CVAC?

Mr. Alexander Zehnder
Chief Executive Officer
Mr. Marco Rau L.L.M., Ph.D.
Gen. Counsel
Mr. Thorsten Schuller
Head of Corporation Communications
Slavica Stevanovic-Heck
Head of HR
Dr. Igor Splawski M.Sc., Ph.D.
Chief Scientific Officer & Member of Management Board
Dr. Ulrike Gnad-Vogt M.D., Ph.D.
Senior Vice President & Area Head of Oncology
Dr. Alexander Zehnder M.B.A., M.D.
Chief Executive Officer, MD & Member of Management Board
Dr. Sarah Fakih
Vice President Corporation Communications & Investor Relations
Dr. Alexander Zehnder
Chief Executive Officer & MD
Dr. Myriam Mendila M.D.
Chief Devel. Officer & Member of the Management Board
Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D.
Managing Director
Dr. Alexander Zehnder L.L.M., Ph.D.
Chief Executive Officer, MD & Member of Management Board
Mr. Pierre Kemula B.Sc.
MD, Chief Financial Officer & Member of Management Board
Dr. Antony Blanc Ph.D.
MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
Mr. Malte Greune Ph.D.
Chief Operating Officer, Member of Management Board & MD

How CVAC did perform over past 52-week?

CVAC's closing price is 29.12% higher than its 52-week low of $2.22 where as its distance from 52-week high of $5.28 is -45.83%.

How many employees does CVAC have?

Number of CVAC employees currently stands at 999.

Link for CVAC official website?

Official Website of CVAC is: https://www.curevac.com

How do I contact CVAC?

CVAC could be contacted at phone 497 071 98830 and can also be accessed through its website. CVAC operates from Friedrich-Miescher-Strasse 15, TÃ¼bingen, 72076, Germany.

How many shares of CVAC are traded daily?

CVAC stock volume for the day was 555.4K shares. The average number of CVAC shares traded daily for last 3 months was 825.34K.

What is the market cap of CVAC currently?

The market value of CVAC currently stands at $641.52M with its latest stock price at $2.86 and 224.31M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	999
Beta	2.53
Sales or Revenue	$52.66M
5Y Sales Change%	2.333%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology